vimarsana.com
Home
Live Updates
LUPKYNIS® (voclosporin) Achieved Significantly Higher R
LUPKYNIS® (voclosporin) Achieved Significantly Higher R
LUPKYNIS® (voclosporin) Achieved Significantly Higher Renal Response in Lupus Nephritis Patients with High Proteinuria Compared to Patients Treated with MMF and Low Dose Steroids Alone
Aurinia Pharmaceuticals Inc. today announced the results of a post-hoc, pooled analysis of the Phase 2 AURA-LV and Phase 3 AURORA 1 studies, which found that LUPKYNIS® with mycophenolate... | June 1, 2023
Related Keywords
Maryland ,
United States ,
Ohio ,
Cleveland ,
Rockville ,
Italy ,
Milan ,
Lombardia ,
Emily Littlejohn ,
Greg Keenan ,
Aurinia Pharmaceuticals ,
Nasdaq ,
European Congress ,
Aurinia Pharmaceuticals Inc ,
Cleveland Clinic Main Campus ,
Immunologic Disease ,
Chief Medical Officer ,
Red Cell Aplasia ,
Drug Interactions ,
Moderate Hepatic Impairment ,
Prescribing Information ,
Boxed Warning ,
Medication Guide ,
Aurinia Pharmaceuticals Inc Stock Exchange ,
News ,
Information ,
Press Release ,
Aurinia ,
Pharmaceuticals ,
Oday ,
Nnounced ,
The ,
Results ,
F ,
Spooled ,
Analysis ,
Hase ,
,
End ,
Aurora ,
Which ,
Hound ,
Hat ,
Ith Auph Ca05156v1022 ,